Director S&T
ADM
Aouatef Bellamine earned her Ph.D. in Toxicology with honors at the Sorbonne University in France. She is a pioneer in the field of cytochrome P450, where she was the first to purify and characterize the CYP51, the enzyme involved in cholesterol synthesis in Mycobacterium tuberculosis. Her research brought her from Vanderbilt University to the industry where she led a program at Bristol-Myers Squibb looking at the safety and the lipodystrophy resulting from the use of protease inhibitors and anti-psychotic drugs. Later at BMS, she joined the metabolic disease medical affairs team where she contributed to the launch of several diabetic drugs. She also led a work stream looking at the off-target effects of DPP-4 inhibitors and their impact on the cardiovascular outcomes, as part of the SAVOR clinical trial. For over 10 years at Lonza, Aouatef was a leading member of the R&D organization in the Nutrition business, where she was involved in the research and the clinical development for the Nutrition portfolio for the purpose of claim substantiation and new applications. At Lonza, she was involved in the development, acquisition and launch of new dietary supplements in both human and animal nutrition. She has a proven record and authored over 35 peer reviewed articles in the fields of lipid metabolism, endocrinology and Nutrition. She also authored several patents both in US and in Europe. She has been invited as a lecturer in many scientific conferences and has been involved in many advisory boards as a spokesperson. Since January 2022, Aouatef joined ADM as a Sr Scientist. Aouatef is a member of the American Association for the Advancement of Science, the American Society of Biochemistry and Molecular Biology, the American Society of Nutrition, the Council for Responsible Nutrition, the American Diabetes Association and the Society of Toxicology.